Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “sell” rating restated by Canaccord Genuity Group in a report issued on Wednesday, Benzinga reports. They currently have a $379.00 target price on the pharmaceutical company’s stock, up from their prior target price of $332.00. Canaccord Genuity Group’s price target indicates a potential downside of […]